Authorities in Henan, China approved changes in Henan Taloph Pharmaceutical Stock's (SHA:600222) drug production license for its honeysuckle dew drops and isatis root syrup, according to a Tuesday filing with the Shanghai bourse.
The company obtained approval for in-house production of its dew drops and syrup, the filing said.
The honeysuckle dew is used for pediatric sores and summer heat, while the syrup is indicated for colds and sore throat.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。